Annual Accounts Receivable
$4.66 B
-$117.00 M-2.45%
31 December 2023
Summary:
Gilead Sciences annual accounts receivable is currently $4.66 billion, with the most recent change of -$117.00 million (-2.45%) on 31 December 2023. During the last 3 years, it has fallen by -$232.00 million (-4.74%). GILD annual accounts receivable is now -20.40% below its all-time high of $5.85 billion, reached on 31 December 2015.GILD Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$4.59 B
-$76.00 M-1.63%
30 September 2024
Summary:
Gilead Sciences quarterly accounts receivable is currently $4.59 billion, with the most recent change of -$76.00 million (-1.63%) on 30 September 2024. Over the past year, it has dropped by -$203.00 million (-4.24%). GILD quarterly accounts receivable is now -25.57% below its all-time high of $6.16 billion, reached on 31 March 2016.GILD Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GILD Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -2.5% | -4.2% |
| 3 y3 years | -4.7% | +0.5% |
| 5 y5 years | +40.1% | +38.4% |
GILD Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -4.7% | +3.7% | -4.2% | +21.1% |
| 5 y | 5 years | -4.7% | +40.1% | -6.2% | +43.6% |
| alltime | all time | -20.4% | +9446.4% | -25.6% | +9296.9% |
Gilead Sciences Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.59 B(-1.6%) |
| June 2024 | - | $4.66 B(-0.1%) |
| Mar 2024 | - | $4.67 B(+0.2%) |
| Dec 2023 | $4.66 B(-2.4%) | $4.66 B(-2.7%) |
| Sept 2023 | - | $4.79 B(+13.3%) |
| June 2023 | - | $4.23 B(+1.6%) |
| Mar 2023 | - | $4.16 B(-12.9%) |
| Dec 2022 | $4.78 B(+6.3%) | $4.78 B(+9.7%) |
| Sept 2022 | - | $4.35 B(+5.7%) |
| June 2022 | - | $4.12 B(+8.7%) |
| Mar 2022 | - | $3.79 B(-15.7%) |
| Dec 2021 | $4.49 B(-8.2%) | $4.49 B(-1.6%) |
| Sept 2021 | - | $4.57 B(+10.1%) |
| June 2021 | - | $4.15 B(+5.7%) |
| Mar 2021 | - | $3.92 B(-19.8%) |
| Dec 2020 | $4.89 B(+36.6%) | $4.89 B(+25.0%) |
| Sept 2020 | - | $3.91 B(+22.5%) |
| June 2020 | - | $3.19 B(-18.2%) |
| Mar 2020 | - | $3.91 B(+9.1%) |
| Dec 2019 | $3.58 B(+7.7%) | $3.58 B(+8.1%) |
| Sept 2019 | - | $3.31 B(-2.4%) |
| June 2019 | - | $3.40 B(+3.4%) |
| Mar 2019 | - | $3.28 B(-1.3%) |
| Dec 2018 | $3.33 B(-13.6%) | $3.33 B(-4.0%) |
| Sept 2018 | - | $3.46 B(-2.1%) |
| June 2018 | - | $3.54 B(-6.2%) |
| Mar 2018 | - | $3.77 B(-2.0%) |
| Dec 2017 | $3.85 B(-14.7%) | $3.85 B(-6.6%) |
| Sept 2017 | - | $4.12 B(-7.9%) |
| June 2017 | - | $4.48 B(+11.0%) |
| Mar 2017 | - | $4.03 B(-10.6%) |
| Dec 2016 | $4.51 B(-22.9%) | $4.51 B(-11.1%) |
| Sept 2016 | - | $5.08 B(-11.8%) |
| June 2016 | - | $5.75 B(-6.7%) |
| Mar 2016 | - | $6.16 B(+5.3%) |
| Dec 2015 | $5.85 B(+26.3%) | $5.85 B(-4.1%) |
| Sept 2015 | - | $6.11 B(+14.5%) |
| June 2015 | - | $5.33 B(+10.3%) |
| Mar 2015 | - | $4.83 B(+4.3%) |
| Dec 2014 | $4.63 B(+112.4%) | $4.63 B(+62.6%) |
| Sept 2014 | - | $2.85 B(-17.1%) |
| June 2014 | - | $3.44 B(+6.2%) |
| Mar 2014 | - | $3.24 B(+48.3%) |
| Dec 2013 | $2.18 B(+24.6%) | $2.18 B(+10.7%) |
| Sept 2013 | - | $1.97 B(+4.0%) |
| June 2013 | - | $1.90 B(-2.5%) |
| Mar 2013 | - | $1.95 B(+11.1%) |
| Dec 2012 | $1.75 B | $1.75 B(-0.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $1.77 B(+3.7%) |
| June 2012 | - | $1.70 B(-21.3%) |
| Mar 2012 | - | $2.16 B(+10.9%) |
| Dec 2011 | $1.95 B(+20.3%) | $1.95 B(+4.5%) |
| Sept 2011 | - | $1.87 B(-3.7%) |
| June 2011 | - | $1.94 B(+7.6%) |
| Mar 2011 | - | $1.80 B(+11.1%) |
| Dec 2010 | $1.62 B(+16.7%) | $1.62 B(-2.9%) |
| Sept 2010 | - | $1.67 B(+12.6%) |
| June 2010 | - | $1.48 B(-0.6%) |
| Mar 2010 | - | $1.49 B(+7.3%) |
| Dec 2009 | $1.39 B(+35.8%) | $1.39 B(+3.8%) |
| Sept 2009 | - | $1.34 B(+7.7%) |
| June 2009 | - | $1.24 B(+16.4%) |
| Mar 2009 | - | $1.07 B(+4.4%) |
| Dec 2008 | $1.02 B(+28.7%) | $1.02 B(-2.3%) |
| Sept 2008 | - | $1.05 B(+2.5%) |
| June 2008 | - | $1.02 B(+4.2%) |
| Mar 2008 | - | $979.80 M(+23.2%) |
| Dec 2007 | $795.13 M(+30.5%) | $795.13 M(-1.1%) |
| Sept 2007 | - | $803.63 M(+9.4%) |
| June 2007 | - | $734.51 M(+6.1%) |
| Mar 2007 | - | $692.07 M(+13.6%) |
| Dec 2006 | $609.32 M(+53.8%) | $609.32 M(+4.1%) |
| Sept 2006 | - | $585.05 M(+19.6%) |
| June 2006 | - | $489.32 M(+12.8%) |
| Mar 2006 | - | $433.63 M(+9.5%) |
| Dec 2005 | $396.13 M(+6.7%) | $396.13 M(-1.1%) |
| Sept 2005 | - | $400.62 M(+7.7%) |
| June 2005 | - | $371.98 M(-3.5%) |
| Mar 2005 | - | $385.44 M(+3.8%) |
| Dec 2004 | $371.25 M(+57.8%) | $371.25 M(+22.0%) |
| Sept 2004 | - | $304.30 M(+9.7%) |
| June 2004 | - | $277.31 M(+7.7%) |
| Mar 2004 | - | $257.49 M(+9.5%) |
| Dec 2003 | $235.22 M(+88.1%) | $235.22 M(+17.0%) |
| Sept 2003 | - | $201.06 M(+0.4%) |
| June 2003 | - | $200.31 M(+37.2%) |
| Mar 2003 | - | $145.98 M(+16.8%) |
| Dec 2002 | $125.04 M(+68.4%) | $125.04 M(+9.6%) |
| Sept 2002 | - | $114.06 M(+12.4%) |
| June 2002 | - | $101.46 M(+31.9%) |
| Mar 2002 | - | $76.94 M(+3.6%) |
| Dec 2001 | $74.23 M(+52.1%) | $74.23 M(+25.0%) |
| Sept 2001 | - | $59.40 M(+9.3%) |
| June 2001 | - | $54.35 M(+6.2%) |
| Mar 2001 | - | $51.19 M(+4.9%) |
| Dec 2000 | $48.81 M | $48.81 M |
FAQ
- What is Gilead Sciences annual accounts receivable?
- What is the all time high annual accounts receivable for Gilead Sciences?
- What is Gilead Sciences annual accounts receivable year-on-year change?
- What is Gilead Sciences quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Gilead Sciences?
- What is Gilead Sciences quarterly accounts receivable year-on-year change?
What is Gilead Sciences annual accounts receivable?
The current annual accounts receivable of GILD is $4.66 B
What is the all time high annual accounts receivable for Gilead Sciences?
Gilead Sciences all-time high annual accounts receivable is $5.85 B
What is Gilead Sciences annual accounts receivable year-on-year change?
Over the past year, GILD annual accounts receivable has changed by -$117.00 M (-2.45%)
What is Gilead Sciences quarterly accounts receivable?
The current quarterly accounts receivable of GILD is $4.59 B
What is the all time high quarterly accounts receivable for Gilead Sciences?
Gilead Sciences all-time high quarterly accounts receivable is $6.16 B
What is Gilead Sciences quarterly accounts receivable year-on-year change?
Over the past year, GILD quarterly accounts receivable has changed by -$203.00 M (-4.24%)